Targeted therapy for mTORC1-driven tumours through HDAC inhibition by exploiting innate vulnerability of mTORC1 hyper-activation

BACKGOUND: The mechanistic target of rapamycin complex 1 (mTORC1) is important in the development and progression of many cancers. Targeted cancer therapy using mTORC1 inhibitors is used for treatment of cancers; however, their clinical efficacies are still limited. METHODS: We recently created a ne...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Fuchun, Sun, Shaogang, Wang, Chenran, Haas, Michael, Yeo, Syn, Guan, Jun-Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7283252/
https://www.ncbi.nlm.nih.gov/pubmed/32336756
http://dx.doi.org/10.1038/s41416-020-0839-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7283252/
https://www.ncbi.nlm.nih.gov/pubmed/32336756
http://dx.doi.org/10.1038/s41416-020-0839-1

Ejemplares similares